In summary, the model changes have led to a higher fair value, SEK 15.19 (10.81) per share.
• Final patient dosed in the phase I study
• Production process of SOL-116 according to plan
• Adjusting the WACC leads to a new fair value of SEK 15.19 (10.81) per share
LÄS MER